Navigation Links
World's First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
Date:10/27/2008

he United States and Bioniche will not be permitted to use the trademark for the vaccine.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Bioniche Life Sciences Inc. is holding a press conference at 10:00 a.m. EDT, on Monday, October 27, 2008. Real-time video webcast of press conference is available online. To view it, go to: http://webcast.marsdd.com/bioniche/2008-10-27/

-------------------------------------------------------------------------

Video News Release will be available via satellite


'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. BODY WORLDS 2 & Breathe California Pair Up for Some Ash Kicking
2. BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008
3. Museum Open Around the Clock - BODY WORLDS 2 and The Tech Host 40 Hour Marathon!
4. The Institute for Plastination Responds to the Bishop of Manchesters Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester
5. Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program
6. California Science Center Welcomes 1-Millionth BODY WORLDS Visitor
7. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
8. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
9. First biomarker discovered that predicts prostate cancer outcome
10. FDA Approves First Anti-Psychotic for Kids
11. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 1Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 1ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 3ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 4ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 5ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 6ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 7ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 8ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 9ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 10ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 11